Scientists Reversed Alzheimer's in Mice. We're Building the Bridge. The mouse study is by the Pieper lab at Case Western (Cell Reports Medicine, 2025) — their work, not ours. The gap between a mouse study and a human therapy is the bridge we are building: sixteen hypotheses certified at AAIC 2026, ready for their first lab tests.
Every family the next diagnosis is coming for is waiting for the same thing: someone to test the ideas honestly, and to publish what works and what doesn't.
Founder, The Reversal Initiative · Former EVP, META Group (now part of Gartner) · AI Researcher Since the 1990s · 20+ Peer-Reviewed Bio Papers
Every tool we build is peer-reviewed. Together they take a hypothesis from target screening to a candidate ready for lab testing.
AI-driven target identification across the NAD+ biosynthesis pathway. Our models evaluate binding affinity, selectivity, and blood-brain barrier penetration to prioritize the most promising intervention points.
Generative chemistry pipelines that design novel neuroprotective compounds. Each candidate is optimized for drug-likeness, synthesizability, and predicted efficacy against validated Alzheimer's mechanisms.
Multi-scale toxicity prediction before any compound reaches a living cell. Off-target binding, hepatotoxicity, cardiotoxicity, and mutagenicity are all flagged computationally — reducing animal testing and accelerating timelines.
Published in Cell Reports Medicine (2025), researchers demonstrated that the P7C3-A20 compound — an NAD+ pathway activator — reversed cognitive decline, reduced amyloid plaques, and restored synaptic function in Alzheimer's mouse models. This is the foundational biology our AI tools are built to accelerate.
Our key application is Alzheimer's reversal, within the broader area of drug design and biological discovery.
DOI: 10.1016/j.xcrm.2025.102535
⚠ Authors: Chaubey K., Vázquez-Rosa E., et al., Case Western Reserve University et al. — This paper is not authored by Neurodegenerative Reversal Research Foundation or AIXC. It is the foundational discovery our computational platform is built to build upon and accelerate.
16 abstracts certified by the Alzheimer's Association at AAIC 2026, London. 15 accepted abstracts at AD/PD 2027, Barcelona. Methods grounded in 29 NeurIPS 2026 workshop papers across drug discovery and biomedical AI.
Built on 28+ peer-reviewed bio papers and production-deployed platforms. Your support takes the first hypotheses from the computer to the lab.
Research partnerships · Tool development · Joint publications
Why we do this: David Scott Lewis lost his mother to Alzheimer’s, and his sister lives with it today.
